- Home
- SNSE vs ICU Comparison
SNSE vs ICU Comparison
Compare SNSE & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNSE
- ICU
- Stock Information
- Founded
- SNSE 2005
- ICU 2018
- Country
- SNSE United States
- ICU United States
- Employees
- SNSE N/A
- ICU N/A
- Industry
- SNSE Biotechnology: Pharmaceutical Preparations
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- SNSE Health Care
- ICU Health Care
- Exchange
- SNSE Nasdaq
- ICU Nasdaq
- Market Cap
- SNSE 10.8M
- ICU 10.4M
- IPO Year
- SNSE 2021
- ICU N/A
- Fundamental
- Price
- SNSE $8.17
- ICU $0.61
- Analyst Decision
- SNSE Strong Buy
- ICU
- Analyst Count
- SNSE 3
- ICU 0
- Target Price
- SNSE $86.67
- ICU N/A
- AVG Volume (30 Days)
- SNSE 12.9K
- ICU 19.2M
- Earning Date
- SNSE 08-05-2025
- ICU 08-12-2025
- Dividend Yield
- SNSE N/A
- ICU N/A
- EPS Growth
- SNSE N/A
- ICU N/A
- EPS
- SNSE N/A
- ICU N/A
- Revenue
- SNSE N/A
- ICU $428,000.00
- Revenue This Year
- SNSE N/A
- ICU $754.07
- Revenue Next Year
- SNSE N/A
- ICU $100.09
- P/E Ratio
- SNSE N/A
- ICU N/A
- Revenue Growth
- SNSE N/A
- ICU N/A
- 52 Week Low
- SNSE $5.00
- ICU $0.31
- 52 Week High
- SNSE $17.40
- ICU $9.56
- Technical
- Relative Strength Index (RSI)
- SNSE 50.67
- ICU 41.48
- Support Level
- SNSE $8.76
- ICU $0.52
- Resistance Level
- SNSE $9.27
- ICU $0.83
- Average True Range (ATR)
- SNSE 0.52
- ICU 0.16
- MACD
- SNSE -0.00
- ICU 0.04
- Stochastic Oscillator
- SNSE 42.84
- ICU 50.89
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.